Docetaxel in Treating Children With Recurrent Solid Tumors
|Brain and Central Nervous System Tumors Neuroblastoma Sarcoma||Biological: filgrastim Drug: docetaxel||Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS|
|Study Start Date:||January 1997|
|Primary Completion Date:||December 2004 (Final data collection date for primary outcome measure)|
Experimental: Arm I
All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.
|Biological: filgrastim Drug: docetaxel|
I. Determine the response rate to docetaxel in children with recurrent sarcomas, neuroblastomas, or brain tumors.
II. Describe the toxic effects of docetaxel in these patients.
All patients receive docetaxel with G-CSF every 21 days for up to 12 courses. Patients are followed for survival.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002825
Show 36 Study Locations
|Study Chair:||Theodore Zwerdling, MD||University of California, Davis|